1. Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer. Issue 13 (14th April 2020) Authors: Conte, PierFranco; Schneeweiss, Andreas; Loibl, Sibylle; Mamounas, Eleftherios P.; von Minckwitz, Gunter; Mano, Max S.; Untch, Michael; Huang, Chiun‐Sheng; Wolmark, Norman; Rastogi, Priya; D'Hondt, Veronique; Redondo, Andrés; Stamatovic, Ljiljana; Bonnefoi, Hervé; Castro‐Salguero, Hugo; Fischer, ... Journal: Cancer Issue: Volume 126:Issue 13(2020) Page Start: 3132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗